229 related articles for article (PubMed ID: 10096254)
1. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ
Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254
[TBL] [Abstract][Full Text] [Related]
2. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma.
Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Van den Heuvel MM; Noordzij MA; Nijman RJ; Soliman EH; van Steenbrugge GJ
Br J Cancer; 2001 Nov; 85(10):1557-63. PubMed ID: 11720445
[TBL] [Abstract][Full Text] [Related]
4. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
5. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
Mayo MW; Wang CY; Drouin SS; Madrid LV; Marshall AF; Reed JC; Weissman BE; Baldwin AS
EMBO J; 1999 Jul; 18(14):3990-4003. PubMed ID: 10406804
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
el Bahtimi R; Hazen-Martin DJ; Re GG; Willingham MC; Garvin AJ
Mod Pathol; 1996 Mar; 9(3):238-44. PubMed ID: 8685221
[TBL] [Abstract][Full Text] [Related]
7. Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.
Hazen-Martin DJ; Re GG; Garvin AJ; Sens DA
Am J Pathol; 1994 May; 144(5):1023-34. PubMed ID: 8178926
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
Salama A; Kamel A
J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
Lahoti C; Thorner P; Malkin D; Yeger H
Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
11. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.
Zuppan CW; Beckwith JB; Luckey DW
Hum Pathol; 1988 Oct; 19(10):1199-209. PubMed ID: 2844645
[TBL] [Abstract][Full Text] [Related]
12. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic protein expression in favorable-histology Wilms tumor correlates with tumor recurrence.
Agarwal S; Iyer VK; Agarwala S; Mathur SR; Aron M; Datta Gupta S; Verma K
Pediatr Surg Int; 2011 Mar; 27(3):303-8. PubMed ID: 20963425
[TBL] [Abstract][Full Text] [Related]
14. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic Wilms' tumor: clinical and pathologic studies.
Bonadio JF; Storer B; Norkool P; Farewell VT; Beckwith JB; D'Angio GJ
J Clin Oncol; 1985 Apr; 3(4):513-20. PubMed ID: 2984344
[TBL] [Abstract][Full Text] [Related]
16. Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric Wilms' tumors.
Ramachandran C; Melnick SJ; Escalon E; Jhabvala P; Khatib Z; Alamo A; Smith S
Anticancer Res; 2000; 20(5C):3759-65. PubMed ID: 11268451
[TBL] [Abstract][Full Text] [Related]
17. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
Bardeesy N; Beckwith JB; Pelletier J
Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
[TBL] [Abstract][Full Text] [Related]
18. Association of E2F3 expression with clinicopathological features of Wilms' tumors.
An Q; Wang Y; An R; Li Y; Yao T; Zhai B; Sun X
J Pediatr Surg; 2013 Nov; 48(11):2187-93. PubMed ID: 24210184
[TBL] [Abstract][Full Text] [Related]
19. Expression and localization of HGF and met in Wilms' tumours.
Alami J; Williams BR; Yeger H
J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
[TBL] [Abstract][Full Text] [Related]
20. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
